Moment of Clarity in Reseda, CA, Continues To Deliver Exceptional Outpatient Mental Health Treatment To Patients In Need
Located at 18627 Keswick St., Reseda, CA 91335, Moment of Clarity offers a serene, well-maintained space where people facing mental health challenges can find the support and structure they need to regain control of their lives. The clinic's services extend to people living throughout the greater San Fernando Valley, including Van Nuys and surrounding neighborhoods. Whether someone is coping with depression, anxiety, trauma, or mood instability, the team at Moment of Clarity uses proven therapeutic techniques to guide them toward lasting wellness. At the heart of their approach is a personalized care model that listens to each patient's story and responds with empathy, evidence-based strategies, and genuine care.
Ronnie's reflection on his time at Moment of Clarity highlights why this mental health center has become a beacon of hope for the local community. He describes a place that is not only professionally structured but also deeply human—a rare blend that gives patients the support they need while preserving their dignity and independence. While the center enforces necessary structure and rules, these systems are in place to ensure a respectful, safe, and healing environment where everyone can thrive. Ronnie's words emphasize that the program works for those willing to engage—and that success is possible for anyone open to change and growth.
The mental health treatment offered at Moment of Clarity Reseda includes various services designed to meet each patient's unique needs. Cognitive behavioral therapy (CBT) is among its most effective offerings, which helps people identify unhelpful thinking patterns and replace them with healthier, more productive thoughts and behaviors. CBT is a cornerstone of the clinic's anxiety disorder treatments, which help patients manage intrusive thoughts, excessive worry, and panic responses that often interfere with daily life. Additionally, Moment of Clarity provides specialized depression treatment programs that help patients find new motivation, set realistic goals, and rebuild a positive sense of self.
As an outpatient mental health treatment provider, Moment of Clarity offers a flexible and accessible model that allows people to maintain their daily responsibilities while receiving the care they need. This is particularly beneficial for working professionals, students, and parents who cannot commit to full-time residential care but still require consistent, structured mental health support. The outpatient approach at Moment of Clarity empowers patients to apply therapeutic insights in real-time, giving them practical tools to handle everyday challenges while progressing in their healing journey.
Moment of Clarity's reputation as a leading mental health center in Reseda is built on its effective treatments and the people who deliver them. The clinic is staffed by compassionate therapists, case managers, and facilitators who are deeply committed to patient outcomes. According to Ronnie, these staff members made his entire experience 'pleasant,' which is no small feat for someone arriving at a low point in life. Their welcoming demeanor, professional insight, and unwavering encouragement create a healing environment that feels safe and motivating. Patients are not treated as numbers but as people whose lives matter.
What continues to set Moment of Clarity apart from other providers in the Los Angeles area is its ability to combine structure with warmth, professionalism with approachability, and science-based care with emotional support. This balance allows patients not only to recover but to thrive. They leave the clinic with new strategies for coping, stronger self-awareness, and the emotional tools to move forward with confidence and clarity. In communities like Reseda and Van Nuys, where mental health needs are increasingly urgent, this type of care can change the trajectory of entire lives and families.
The power of patient testimonials like Ronnie's should not be underestimated. In his words, 'Very highly recommended!!!!' speaks volumes about the quality of care he received. These experiences are echoed by many others who have found healing at Moment of Clarity and who continue to share their journeys with others in need. The center's growing reputation across the San Fernando Valley reflects its success in helping people reclaim their peace of mind and emotional strength.
For anyone in the Reseda or Van Nuys area seeking outpatient mental health treatment, Moment of Clarity offers a professional, welcoming, and results-oriented approach that is both accessible and impactful. To learn more about the clinic's services or to schedule a confidential consultation, visit their website.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Teva's Ajovy becomes first migraine prevention drug approved for children
The US Food and Drug Administration (FDA) has approved a label expansion to Teva's Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group. Single-dose injectable Ajovy (fremanezumab-vfrm) is now approved for the preventive treatment of episodic migraine in children and adolescent patients aged between six and 17 years who weigh 45kg or more. Ajovy is part of a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors, which block a protein involved in triggering migraines. The FDA approved Ajovy for adults in 2018. Israel-based Teva narrowly missed having the first CGRP-targeting drug approved for migraines at the time, following Novartis and Amgen's Aimovig (erenumab) approval earlier in the year. However, the therapy is not approved for children or adolescents, meaning its patient reach is now not as wide as Ajovy. One in ten children and adolescents in the US suffers from migraines, one of the most common neurological conditions. Paediatric migraine is often underrecognised and undertreated, disrupting lifestyle such as school attendance and social interactions. Episodic migraine refers to recurring severe headaches in children that do not occur daily but are frequent enough to interfere with daily activities. Ajovy is administered once a month and available for in-office or at-home use, offering an accessible treatment option for patients and their caregivers, such as parents. A higher-dose version, given every three months as three injections, is also available for adults. Teva's Phase III SPACE trial (NCT03539393) with the drug demonstrated statistically significant superior efficacy compared to placebo over three months in the paediatric population. The safety profile was consistent with that in the adult population – the most common side effects being itchiness, rash and drug hypersensitivity. Teva's global marketing business head Chris Fox said: 'Migraines are a common yet invisible condition that can severely disrupt daily life for children and adolescents, often leaving them overlooked and misunderstood. 'With this FDA approval, Ajovy now offers younger patients a new treatment option, addressing a long-standing gap in care and offering families added support as they navigate the challenges of this condition.' The label expansion in children and adolescents gives Teva an edge over Novartis/Amgen, as well as Eli Lilly, whose Emgality (galcanezumab) – also a CGRP inhibitor – is also approved and on the market. Last year, Teva's migraine treatment Ajovy generated $507m in global sales, an 18% increase compared to the previous year. Analysis by GlobalData forecasts sales of $885m by 2031. Neither Amgen nor Lilly disclosed specific sales for their two products in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Teva's Ajovy becomes first migraine prevention drug approved for children" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Navigating ADHICS Compliance: How MIT Consultants is Shaping Cybersecurity Standards in UAE Healthcare
Dubai, UAE,, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As UAE healthcare and financial institutions race to meet stringent ADHICS regulations, MIT Consultants emerges as a trusted advisor, guiding enterprises toward robust compliance through tailored cybersecurity solutions. The cybersecurity landscape in the UAE has dramatically evolved, with healthcare and financial institutions facing heightened regulatory demands under the Abu Dhabi Healthcare Information and Cyber Security Standards (ADHICS). Recent high-profile data breaches and cyber threats have highlighted the urgent need for organizations to comply fully with these standards, protecting sensitive patient and financial information. As organizations scramble to adapt, MIT Consultants, a Dubai-based cybersecurity advisory and solutions reseller, is becoming a pivotal player in assisting healthcare and financial institutions in navigating the complexities of ADHICS compliance. Expert Advisors, Tailored Solutions MIT Consultants differentiates itself through its vendor-neutral advisory approach, ensuring that the solutions recommended are best suited to each organization's specific operational and compliance needs. Rather than advocating for a particular product, the firm's cybersecurity experts thoroughly analyze an institution's existing infrastructure, identify vulnerabilities, and align their recommendations precisely with ADHICS requirements. "Our role goes beyond mere reselling of cybersecurity solutions," says Mohamed Moussous, CEO of MIT Consultants. "We see ourselves as strategic partners. Our clients benefit from our ability to pinpoint precisely what's needed to achieve compliance efficiently and securely." Addressing Critical Cybersecurity Needs Healthcare and financial institutions face particular vulnerabilities—ransomware, phishing attacks, insider threats—all of which ADHICS compliance seeks to mitigate through rigorous cybersecurity measures. MIT Consultants addresses these threats by implementing robust Privileged Access Management (PAM), real-time threat detection systems, patch management processes, and secure information management strategies tailored specifically to ADHICS regulations. Real-World Successes MIT Consultants has successfully guided numerous institutions through ADHICS compliance by identifying gaps, providing detailed roadmaps, and recommending integrated solutions from global cybersecurity vendors. Their expertise ensures minimal operational disruption while achieving full regulatory adherence, ultimately safeguarding institutions from both cyber threats and potential regulatory penalties. "With our deep understanding of the UAE cybersecurity landscape, we provide not just technical solutions but peace of mind," adds Moussous. "Our clients trust us because we have their best interests at heart, which is compliance, security, and operational efficiency." A Strategic Advantage In an environment where regulatory compliance and cybersecurity intersect critically, MIT Consultants offers UAE healthcare and financial institutions a significant strategic advantage. By entrusting compliance initiatives to specialized cybersecurity advisors, organizations can stay ahead of threats, ensure adherence to regulations, and maintain a secure operational environment. As ADHICS continues to shape the future of cybersecurity compliance in the UAE, MIT Consultants stands out as an indispensable ally, turning complex regulatory challenges into clear, actionable strategies. Mohamed Moussous, CEO of MIT ConsultantsIRIS BAY - Business Bay Dubai Website: of the Group : CONTACT: mmoussous@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
3 hours ago
- Business Wire
Northwell's Staten Island University Hospital Performs First U.S. Procedure With New BioHealx Device for Complex Anal Fistulas
STATEN ISLAND, N.Y.--(BUSINESS WIRE)--Northwell's Staten Island University Hospital (SIUH) is the first medical center in the United States to perform surgery using the newly FDA-cleared BioHealx ®Anal Fistula Device - offering new hope to patients suffering from complex and often debilitating anal fistulas. The procedures were performed by colorectal surgeons Poppy Addison, MD, and Giovanni Bonomo, MD, director of colorectal surgery. The BioHealx device, developed by Irish-based Signum Surgical, represents a significant advancement in the treatment of complex anal fistulas, notoriously difficult to treat with current surgical options. The minimally invasive, absorbable implant is designed to close fistula tract as it traverses the anal sphincter complex, without involving any significant disruption of the anorectal anatomy. Early European data demonstrated an 84% success rate, far exceeding traditional approaches that often have success rates closer to 60% and are associated with the need for multiple procedures to finally achieve healing. 'Historically, these surgeries have been long, complex, traumatic to the anorectum and carried the risk of recurrence and incontinence,' said Dr. Bonomo. 'The BioHealx device is intuitive, efficient, and minimizes surgical trauma. If we can replicate the European outcomes, this could set a new standard of care in fistula treatment.' Approximately, 90,000 complex anal fistula procedures are performed yearly. These fistulas predominantly affect men between ages 18 and 50, and disrupts their quality of life due to anal pain, foul-smelling drainage, and recurrent infection. Fistulas can recur even after what appears to be healing at the skin level due to persistence of the transsphincteric fistula tract, and many patients undergo multiple interventions before finding relief. 'Rectal fistulas are under-researched and have lacked a reliable, standardized solution,' said Dr. Addison. 'This device has the potential to optimize care, shorten recovery, and reduce recurrence, all while preserving continence, which is a critical concern for our patients.' Before surgery, a seton drain is placed to help mature the fistula tract and to provide for clear identification of the internal fistula opening. During the BioHealx procedure, the seton is removed, the tract is brushed clean, and a small flap is created to expose the internal sphincter at the location of internal opening. The corkscrew-shaped BioHealx implant is then inserted to compress the tissue around the fistula tract as it traverses the width of the sphincter complex to deliver primary healing by direct tissue apposition. The flap is closed over the internal opening and internal anal sphincter, while the outer tract is partially opened for optimal drainage - all without damaging the sphincter muscle nor disrupting the anal canal. The implant itself is made from bioabsorbable polylactic glycolic acid and naturally dissolves in the body within six to twelve months, leaving no permanent material behind. The inspiration for the BioHealx device dates back to 2013 when engineers Eoin Bambury and Moshe Zilversmit, co-founders of Signum Surgical, met during a government-sponsored fellowship in Ireland. After observing the repeated failure of traditional surgeries to treat anal fistulas, often requiring four or more operations, they launched Signum Surgical in 2016 to develop a better solution. 'The key was identifying the failure of primary healing of the transsphincteric portion of the fistula tract as the root cause of surgical failure,' said Bambury. 'Our goal was to close it effectively without damaging the anal canal nor the anal sphincter. After years of research, clinical trials, and design refinement, we're proud to see our work helping patients here in the U.S.' SIUH's successful completion of the first U.S. procedures using the BioHealx device represents a critical milestone in the adoption of innovative, patient-centered technology across Northwell Health. 'Northwell has always championed advanced technologies that improve outcomes and quality of life,' said Dr. Bonomo. 'This is the kind of breakthrough that can change how we treat complex anal fistulas nationwide.' Drs. Bonomo and Addison will continue evaluating patient outcomes to help guide future adoption and research of the BioHealx procedure. With a shorter learning curve than many other surgical techniques, the team believes the procedure can be easily adopted across the entire system. 'We're incredibly optimistic,' said Dr. Addison. 'This device doesn't burn any bridges - it's safe, effective, and easy to use. If it doesn't work, patients still have all their future options with essentially normal anorectal anatomy. But if it does, it can spare them years of painful, frustrating treatments.'